The U.S. Food and Drug Administration approved Eli Lilly’s Verzenio (abemaciclib) for a specific type of early breast cancer that is at high risk of recurrence after surgery. 

Pfizer’s Phase III study assessing Ibrance as a potential treatment for early breast cancer patients who have residual invasive disease following neoadjuvant chemotherapy failed to meet the clinical trial’s primary endpoint.